Drug Trial Radar · NCT06277219
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 5, 2024
Primary completion
Dec 2026
Study completion Mar 2027
Sponsor
- Lead sponsor
- Latticon Antibody Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.
Conditions
- Advanced Solid Tumor
Interventions
LAT010Drug
LAT010 monotherapy
LAT010 + ICIDrug
LAT010 combination with PD-1 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Phase 1)Time frame: Up to 18 months
- Incidence of changes in clinical laboratory values (Phase 1)Time frame: Up to 15 months
- Incidence of dose-limiting toxicities (DLTs) (Phase 1)Time frame: The first treatment cycle (28 days) from Cycle 1 Day 1
- Objective response rate (ORR) per RECIST 1.1 (Phase 2)Time frame: Up to 24 months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
D&H Cancer Research Center
Margate, Florida · Completed
Huntsman Cancer Institute
Salt Lake City, Utah · Terminated
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.